Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial

被引：1
|
作者：
Park, H. [1 ]
Sanjeevaiah, A. [2 ]
Suresh, R. [1 ]
Mehta, R. [3 ]
Trikalinos, N. [1 ]
Bagegni, N. [1 ]
Aranha, O. [1 ]
Pedersen, K. [1 ]
Nixon, A. [4 ]
Jin, R. [1 ]
Mills, J. [1 ]
Fields, R. [1 ]
Amin, M.
Lim, K.
Tan, B. [1 ]
Grierson, P. [1 ]
Jiang, S. [1 ]
del Rosario, M. [1 ]
Wang-Gillam, A. [1 ]
Lockhart, A. [5 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
[5] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-131
引用
收藏
页码：S132 / S132
页数：1
相关论文
共 50 条
  • [1] Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial
    Park, Haeseong
    Sanjeevaiah, Aravind
    Hosein, Peter Joel
    Mehta, Rutika
    Jin, Ramon
    Grierson, Patrick
    Suresh, Rama
    Aranha, Olivia
    Trikalinos, Nikolaos A.
    Bagegni, Nusayba Ali
    Pedersen, Katrina Sophia
    Lim, Kian-Huat
    Nixon, Andrew B.
    Mills, Jason
    Fields, Ryan
    Tan, Benjamin R.
    Liu, Jingxia
    Brown, Amberly
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
    Park, Haeseong
    Trikalinos, Nikolaos
    Sanjeevaiah, Aravind
    Pedersen, Katrina
    Bagegni, Nusayba Ali
    Nixon, Andrew B.
    Huffman, Jesse
    Tan, Benjamin R.
    Suresh, Rama
    Lim, Kian-Huat
    Amin, Manik A.
    Wang-Gillam, Andrea
    Lockhart, A. Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A phase II study of cabazitaxel in patients with previously treated metastatic gastroesophageal adenocarcinoma
    Austin, Trevor Clark
    Perez, Kimberly
    Fontes-Borts, Lucia
    Luppe, Denise
    Jean, Maureen
    Olszewski, Adam J.
    Rosati, Kayla
    Rathore, Bharti
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Enzinger, PC
    Kulke, MH
    Clark, JW
    Ryan, DP
    Kim, H
    Earle, CC
    Vincitore, MM
    Michelini, AL
    Mayer, RJ
    Fuchs, CS
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (12) : 2218 - 2223
  • [5] A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma
    Peter C. Enzinger
    Matthew H. Kulke
    Jeffrey W. Clark
    David P. Ryan
    Haesook Kim
    Craig C. Earle
    Michele M. Vincitore
    Ann L. Michelini
    Robert J. Mayer
    Charles S. Fuchs
    Digestive Diseases and Sciences, 2005, 50 : 2218 - 2223
  • [6] Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
    Allyson J. Ocean
    Paul Christos
    Joseph A. Sparano
    Manish A. Shah
    Rhonda K. Yantiss
    Jonathan Cheng
    Juan Lin
    Michael Papetti
    Dan Matulich
    Felice Schnoll-Sussman
    Christen Besanceney-Webler
    Jenny Xiang
    Maureen Ward
    Kaili Temple Dilts
    Roger Keresztes
    Shannon Holloway
    Eric X. Chen
    John J. Wright
    Maureen E. Lane
    Investigational New Drugs, 2014, 32 : 542 - 548
  • [7] Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
    Ocean, Allyson J.
    Christos, Paul
    Sparano, Joseph A.
    Shah, Manish A.
    Yantiss, Rhonda K.
    Cheng, Jonathan
    Lin, Juan
    Papetti, Michael
    Matulich, Dan
    Schnoll-Sussman, Felice
    Besanceney-Webler, Christen
    Xiang, Jenny
    Ward, Maureen
    Dilts, Kaili Temple
    Keresztes, Roger
    Holloway, Shannon
    Chen, Eric X.
    Wright, John J.
    Lane, Maureen E.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 542 - 548
  • [8] CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME)
    Saeed, Anwaar
    Park, Robin
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Saeed, Azhar
    Ng, Elizabeth
    Thompson, Kayra
    Moya, Stephanie
    Barbosa, Lori
    Phadnis, Milind
    Williamson, Stephen K.
    Baranda, Joaquina Celebre
    Sun, Weijing
    Catenacci, Daniel V. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
    Nishio, M.
    Ohyanagi, F.
    Horikike, A.
    Okano, Y.
    Satoh, Y.
    Sakae, O.
    Ishikawa, Y.
    Nakagawa, K.
    Nakagawa, K.
    Horai, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Okano, Yoshio
    Satoh, Yukitoshi
    Okumura, Sakae
    Ishikawa, Yuichi
    Nakagawa, Ken
    Horai, Takeshi
    Nishio, Makoto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 503 - 508
12345